A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer

Article

Abstract: Nimotuzumab is a humanized IgG1 monoclonal antibody against the EGFR extracellular domain that has b

Palabras claves:

Advanced cervical cancer, eGFR, Monoclonal antibody, nimotuzumab, Pilot study

Autores:

Astudillo H., Avila S., Bazán B., Bojalil R., Cetina L., Charco E., Coronel J., Dueñas-Gonzãlez A., Jiménez-Lima R., Ramos M., Tania Crombet, Zapata S.

Fuentes:

scopus